Table 1.

PICO framework used for study selection.

Criteria	Inclusion criteria	Exclusion criteria
Population	Patients with colorectal cancer (any stage, any line of treatment) carrying a KRAS G12C mutation	Tumor types other than colorectal cancer
Intervention	Any anticancer drugs, any line of treatment, or no treatment	Radiotherapy or surgery (unless a relevant comparator arm)
Comparator	Any or none	Not applicable
Outcome	Outcome reported by KRAS G12C mutation status Epidemiological evidence • Prevalence of KRAS G12C mutation • KRAS mutation and subtypes Clinical evidence • Overall survival • Progression-free survival • Disease-free survival • Adverse events • Objective response rate • Time to response • Duration of response	Not applicable
Study design	Any randomized controlled trial, single-arm trial, observational study	Exclude animal/in vitro studies, case studies, and case reports
Date restrictions	• Published since 2009 • Congress abstracts published since 2016	Published before 2009
Language restrictions	English language	Non-English language
Publication type	All publication types, except editorials and reviews, but including systematic reviews	Editorials and reviews
Country	Not restricted	Not applicable

Abbreviations: KRAS, Kirsten rat sarcoma virus gene; KRAS G12C, KRAS with mutation at codon 12 that results in the substitution of glycine with cysteine; PICO, Population, Intervention, Comparator, Outcome.